Research protocol to identify progression and death amongst patients with metastatic hormone-sensitive prostate cancer treated with available treatments: PIONEER IMI’s “big data for better outcomes” program

Androgen deprivation therapy-based with or without first-generation anti-androgens, was the standard of care for patients with metastatic hormone-sensitive prostate cancer (mHSPC) for decades. However, the development of docetaxel chemotherapy and new androgen receptor-targeted agents, abiraterone a...

Descripción completa

Detalles Bibliográficos
Autores principales: Gomez Rivas, Juan, Nicoletti, Rossella, Ibáñez, Laura, Steinbeisser, Carl, de Meulder, Bertrand, Golozar, Asieh, Axelsson, Susan Evans, Snijder, Robert, Bjartell, Anders, Cornford, Philip, Van Hemelrijck, Mieke, Beyer, Katharina, Willemse, Peter-Paul, Murtola, Teemu, Roobol, Monique J., Moreno-Sierra, Jesús, Campi, Riccardo, Gacci, Mauro, Mottet, Nicolas, Merseburger, Axel, Ndow, James
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10688536/
https://www.ncbi.nlm.nih.gov/pubmed/38046899
http://dx.doi.org/10.1097/SP9.0000000000000009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10688536/
https://www.ncbi.nlm.nih.gov/pubmed/38046899
http://dx.doi.org/10.1097/SP9.0000000000000009

Ejemplares similares